Medivir AB (publ) (LON:0GP7)

Market Cap	87.61M +395.3%
Revenue (ttm)	716.66K +151.3%
Net Income	-7.20M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	515
Open	1.802
Previous Close	1.806
Day's Range	1.800 - 1.818
52-Week Range	0.404 - 2.875
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone deacetylase (HDAC) inhibitor that is in a Phase II trial for the treatme...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1987
• Employees: 7
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GP7

Financial Performance

In 2025, Medivir AB's revenue was 8.51 million, an increase of 144.14% compared to the previous year's 3.48 million. Losses were -94.40 million, -23.45% less than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 12, 2026

Data Sources Report a data error